1. Home
  2. FDMT vs EVO Comparison

FDMT vs EVO Comparison

Compare FDMT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 4D Molecular Therapeutics Inc.

FDMT

4D Molecular Therapeutics Inc.

N/A

Current Price

$13.38

Market Cap

695.3M

Sector

Health Care

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

N/A

Current Price

$1.53

Market Cap

568.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FDMT
EVO
Founded
2013
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
695.3M
568.6M
IPO Year
2019
2007

Fundamental Metrics

Financial Performance
Metric
FDMT
EVO
Price
$13.38
$1.53
Analyst Decision
Strong Buy
Buy
Analyst Count
12
3
Target Price
★ $28.09
$4.17
AVG Volume (30 Days)
★ 942.7K
160.9K
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.79
N/A
EPS
N/A
★ N/A
Revenue
★ $85,209,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$55.65
$20.51
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 230194.60
N/A
52 Week Low
$6.96
$1.50
52 Week High
$16.93
$4.27

Technical Indicators

Market Signals
Indicator
FDMT
EVO
Relative Strength Index (RSI) 46.71 36.74
Support Level $13.39 $1.50
Resistance Level $14.00 $1.97
Average True Range (ATR) 0.92 0.05
MACD -0.22 0.01
Stochastic Oscillator 32.85 10.23

Price Performance

Historical Comparison
FDMT
EVO

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: